Pharmacyclics — Technical Presentation (June 2013)
17 slides from Pharmacyclics's technical presentation, Jun 3, 2013
Slide 1: Phase 1b Study Combining Ibrutinib With R-CHOP in CD20-Positive B-Cell NHL
PCI-32765DBL1002 Phase 1b Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients With CD20-Positive B-Cell Non-Hodgkin Lymphoma (NHL) Anas Younes, lan Flinn,? Jesus Berdeja,? Jonathan Friedberg? Sara Alberti,> Catherine Thieblemont,*
Slide 2: Background
Background + Ibrutinib (PCI-32765) is a first-in-class oral covalent Bruton’s tyrosine kinase (BTK) inhibitor that has demonstrated single-agent activity in a variety of relapsed or refractory B-cell malignancies with limited toxicity’ » R-CHOP is the currently accepted standard of care for a number
Slide 3: Study Objectives
Study Objectives ° Primary objective — To determine the recommended phase 2 dose and dose limiting toxicities (DLT) of ibrutinib in combination with standard R-CHOP therapy in treatment-naive patients with NHL * Secondary objectives — To assess safety (adverse event [AE] profile) — To evaluate pharm
Slide 4: Study Design
Study Design Part 1: dose escalation (3+3 pts / dose level) Ibrutinib 420 mg Ibrutinib 560 mg + R-CHOP + R-CHOP Ibrutinib 280 mg +R-CHOP Part 2: dose expansion at recommended phase 2 dose (15 patients) Newly diagnosed treatment-naive DLBCL Ibrutinib 560 mg + R-CHOP Filia ye dy M ‘ M rutinib continuo
Slide 5: Patient Eligibility
Patient Eligibility Aged 18 years or older Treatment-naive, histopathologically confirmed CD20-positive B-cell NHL (DLBCL, MCL, or FL) Stage |,x (single lymph node mass > 10 cm in diameter) to stage IV disease At least 1 measurable disease site Eastern Cooperative Oncology Group (ECOG) score of 0-2
Slide 6: Patient Demographics/Characteristics
Patient Demographics/Characteristics Ibrutinib + R-CHOP Age, years Median (range) 68.0 (60-81) 58.0(46-74) 66.5(64-77) 50.0 (22-72) Sex, n (%) Male 467.1) 3 (75.0) 2 (33.3) 8 (63.1) Female 3 (42.9) 4 (25.0) 4 (66.7) 7 (46.9) NHL subtype, n (%) DLBCL 3 (42.9) 2 (60.0) 3 (60.0) 15 (100.0) MCL 3.(42.9)
Slide 7: Patient Disposition
Patient Disposition Ibrutinib + R-CHOP Received ibrutinib, n 7 4 6 15 Completed first cycle of therapy, n 6 4 6 15 Completed full treatment (6 cycles), n 6 4 5 0 Premature discontinuation, n 12 0 ae 0 + Part 4 *1 DLBCL patient discontinued due to non-compliance (only 1 daily-dose received) >1 FL pat
Slide 8: DLT and Recommended Phase 2 Dose
DLT and Recommended Phase 2 Dose In the 280 mg cohort, 2 patients had a DLT: — 1 with brief syncope (grade 3)? — 1 with peri-orbital cellulitis (grade 3)> » Inthe 560 mg group, 1 patient had a DLT: — 1 with gastritis (grade 2) associated with dose interruption of ibrutinib > 7 days® MTD was not reac
Slide 9: All-Grade AEs (>25%) Irrespective of Association with Ibrutinib + R-CHOP
All-Grade AEs (> 25%) Irrespective of Association with Ibrutinib + R-CHOP? Patients with > 1 AE, n (%) Neutropenia, n (%) Thrombocytopenia, n (%) Nausea, n (%) Vomiting, n (%) Anemia, n (%) Headache, n (%) Diarthea, n (%) Constipation, n (%) Fatigue, n (%) Infusion-related reaction, n (%) 7 (100.0)
Slide 10: Grade ≥3 AEs Irrespective of Association with Ibrutinib + R-CHOP
Grade 2 3 AEs Irrespective of Association with Ibrutinib + R-CHOP? Pts with = 1 AE G23, n (%) 6 (85.7) Neutropenia, n (%)? 6 (85.7) Thrombocytopenia, n (%)° 4 (67.1) Anemia, n (%)° 4 (67.1) Febrile neutropenia, n (%) 2 (28.6) Syncope, n (%) 1(143) 4 (100.0) 4 (100.0) 4 (25.0) 0(0.0) 0(0.0) 4 (25.0)
Slide 11: Pharmacokinetics
Pharmacokinetics » R-CHOP did not effect the pharmacokinetics of ibrutinib — Exposure levels of ibrutinib with R-CHOP were consistent with data from previous single-agent studies in other B-cell malignancies * Ibrutinib did not alter vincristine (CYP3A4 substrate) pharmacokinetics PoLszvesoeLto02
Slide 12: Activity in Evaluable Population
Activity in Evaluable Population * ORR 100% (CR 67%, PR 33%) cr z @ PR 6 2 | wa | § 5 : | S a 4 >, Zz 5 Assessment 2 formed at en | erie 2 = exalaton 1 complete 0+ 280 mg | 420 mg | n=6 n=4 CR, complete response; PR, partial response. All patients were evaluated by PET and CT. Data cutoff 1-May-2013
Slide 13: Conclusions
Conclusions The combination of ibrutinib and R-CHOP can be safely administered No pharmacokinetic interaction between ibrutinib and R-CHOP Recommended phase 2 dose was established at 560 mg ibrutinib + R-CHOP Preliminary activity shows that the addition of ibrutinib to R-CHOP therapy was associated
Slide 14: Acknowledgements
Acknowledgements + We would like to thank the patients and their families for whom without their support this trial would not have been possible + Thanks to the investigators, the study coordinators and their study teams + Thanks to the PCI-32765DBL1002 study team including but not limited to Elisa
Slide 15: PoLs27es08L1002
PoLs27es08L1002
Slide 16: Pharmacokinetics
Pharmacokinetics Period 1 Day3 Period 2Day1 0 a 00 eso at TBS ag 23 qn tf = i: ie as 50 Zs 200. 35 Feo 3 iio gi = 2 8 0. 8 ©. a a a | PoLszvesoeLto02
Slide 17: Safety: Serious AEs (SAEs)
Safety: Serious AEs (SAEs)? Ibrutinib + R-CHOP Pts with 2 1 SAE, n (%) 5 (71.4) 1 (25.0) 1 (16.7) 5 (33.3) Febrile neutropenia, n (%) 2 (286) 0 (0.0) 0 (0.0) 2(13.3) Syncope, n (%) 0 (0.0) 1 (25.0) 4 (16.7) 0 (0.0) Pyrexia, n (%) 0 (0.0) 0 (0.0) 00.0) 2(13.3) Chest pain, n (%) 4 (143) 00.0) 00.0) 0(